GLP-1 受体激动剂治疗改善血糖控制对糖尿病视网膜病变的影响。
The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy.
机构信息
Department of Diabetes and Endocrinology, University Hospital of North Staffordshire NHS Trust, Trent Building, Stoke-on-Trent ST4 6QG, United Kingdom.
Department of Diabetes and Endocrinology, University Hospital of North Staffordshire NHS Trust, Trent Building, Stoke-on-Trent ST4 6QG, United Kingdom; Department of Ophthalmology, University Hospital of North Staffordshire NHS Trust, Trent Building, Stoke-on-Trent ST4 6QG, United Kingdom.
出版信息
Diabetes Res Clin Pract. 2014 Mar;103(3):e37-9. doi: 10.1016/j.diabres.2013.12.041. Epub 2014 Jan 6.
Rapid improvement in glycaemic control with GLP-1 receptor agonist (RA) therapy has been reported to be associated with significant progression of diabetic retinopathy. This deterioration is transient, and continuing GLP-1 RA treatment is associated with reversal of this phenomenon. Pre-existent maculopathy, higher grade of retinopathy and longer duration of diabetes may be risk factors for persistent deterioration.
研究表明，GLP-1 受体激动剂（RA）治疗可迅速改善血糖控制，但与糖尿病视网膜病变的显著进展有关。这种恶化是暂时的，继续使用 GLP-1 RA 治疗与逆转这种现象有关。预先存在的黄斑病变、更严重的视网膜病变和更长的糖尿病病程可能是持续恶化的危险因素。
Zotero 插件